二甲双胍对晚期糖基化终产物诱导的血管平滑肌细胞增殖的影响

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (12): 1368-1372.

二甲双胍对晚期糖基化终产物诱导的血管平滑肌细胞增殖的影响

方丽娟, 刘乃丰

东南大学心血管研究所,南京210009,江苏

收稿日期:2010-11-09 修回日期:2010-12-12 出版日期:2010-12-26 发布日期:2020-09-16
通讯作者: 刘乃丰,男,博士,教授,博士研究生导师,研究方向:血管钙化及动脉粥样硬化发病机制的分子细胞学与临床影像学诊断研究。Tel: 025 -83272001 E-mail: liunf@seu.eud.cn
作者简介:方丽娟,女,在读硕士研究生,主要从事血管钙化、动脉粥样硬化的机制研究。Tel: 025 -83272595 E-mail: fanglj1985@yahoo.cn

Effects of metformin on the proliferation of vascular smooth muscle cells induced by advanced glycation end products

FANG Li-juan, LIU Nai-feng

Institute of Cardiovascular Medicine, Southeast University, Nanjing 210009,Jiangsu, China

Received:2010-11-09 Revised:2010-12-12 Online:2010-12-26 Published:2020-09-16

摘要/Abstract

摘要： 目的: 观察晚期糖基化终产物(advanced glycation endproducts, AGEs)对血管平滑肌细胞(vascular smooth muscle cells, VSMCs)增殖的影响及二甲双胍的干预作用。方法: 生长状态良好的VSMCs,用不同浓度的AGEs (50、100、200、400 mg/L)干预细胞不同时间(12、24、48、72 h);不同浓度的二甲双胍(10^-3,10^-4,5×10^-5,10^-5,10^-6 mol/L)与 200 mg/L AGEs共干预不同时间(12、24、48、72 h),MTT法测定VSMCs增殖。结果: 50 mg/L AGEs干预 72 h 时表现出促进增殖的作用,200 mg/L AGEs干预 12 h 即有增殖促进作用,24 h 时作用最强,400 mg/L AGEs各时间点作用同 200 mg/L AGEs组;10^-3与10^-4 mol/L二甲双胍干预 24 h 抑制作用最强,持续到 72 h, 10^-6 mol/L抑制增殖作用降低,24 h 起效,72 h 时仍有作用。结论: AGEs呈浓度和时间依赖性地促进VSMCs增殖;二甲双胍可抑制AGEs诱导的VSMCs增殖作用。

关键词: 二甲双胍, 晚期糖基化终产物, 细胞增殖

Abstract: AIM: To observe the effects of advanced glycation end products on the proliferation of vascular smooth muscle cells(VSMCs) and how the course are interfered with metformin.METHODS: Well-conditioned VSMCs were dealed with different concentrations of advanced glycation end products (50,100,200,400 mg/L) in different times (12,24,48,72 h). On the basis of above treatments, different concentrations of metformin (10^-3,10^-4,5×10^-5,10^-5,10^-6 mol/L) were given to interfere VSMCs, combined with the 200 mg/L AGEs on different times (12,24,48,72 h). The proliferation of VSMCs was measured by MTT.RESULTS: 50 mg/L AGEs could promote the proliferation of VSMCs at the time point of 72 h; 200 mg/L AGEs began to play the role of promotion at the time point of 12 h, furthermore, 24 h were the strongest. The effects of 400 mg/L AGEs was similar to those of 200 mg/L AGEs at all the time points. 10^-3 mol/L and 10^-4 mol/L metformin had the strongest effects of inhibition at the time point of 12 h, and this effect continued to 72 h. 10^-6 mol/L metformin had lower inhibition on proliferation and its effective time was from 24 h to 72 h.CONCLUSION: AGEs can promote the proliferation of vascular smooth muscle cells in a concentration- and time- dependent manner; metformin can inhibit the proliferation of vascular smooth muscle cells induced by AGEs.

Key words: Metformin, Advanced glycation end products, Cell proliferation

中图分类号:

R965.2

方丽娟, 刘乃丰. 二甲双胍对晚期糖基化终产物诱导的血管平滑肌细胞增殖的影响[J]. 中国临床药理学与治疗学, 2010, 15(12): 1368-1372.

FANG Li-juan, LIU Nai-feng. Effects of metformin on the proliferation of vascular smooth muscle cells induced by advanced glycation end products[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1368-1372.

参考文献

[1] Jandel Eit-Dahm K, Watson A, Soro-Paavonen A. The AGE/RAGE axis in diabetes accelerated atherosclerosis [J]. Clin Exp Pharmacol Physiol, 2008 , 35(3) :329-334.
[2] Kaneda H,Taguchi J,Ogasawara K,et al.Increased level of advanced oxidation protein products in patients with coronary artery disease[J].Atherosclerosis,2002,162(1):221-225.
[3] 张卫茹, 侯凡凡, 刘尚喜.晚期糖基化终产物通过氧化应激加速动脉粥样硬化斑块形成[J].中华医学杂志,2004,84(13):l066-1070.
[4] Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products sparking the development of diabetic vascular injury [J]. Circulation, 2006, 114(6):597-605.
[5] 袁晓晨,刘乃丰,张昕. 吡格列酮和厄贝沙坦对糖基化终产物诱导血管平滑肌细胞增殖的影响[J].中国新药与临床杂志,2006,25(7):501-504.
[6] American Diabetes Association. Standards of medical care in diabetes-2008 [J]. Diabetes Care, 2008, 31(Suppl 1):S12-S54.
[7] Lund SS, Tarnow L, Frandsen M, et al. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in nonobese patients with type 2 diabetes [J]. Eur J Endocrinol, 2008,158 (1): 35-46.
[8] Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin[J]. Diabetes, 2005, 54 (8) : 2404-2414.
[9] Isoda K, Young JL, Zirlik A,et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells [J]. Arterioscler Thromb Vasc Biol,2006,26(3):611-617.
[10] Gómez-García A, Martínez Torres G, Ortega-Pierres LE. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia[J]. Rev Esp Cardiol,2007, 60(12):1242-1249.
[11] Li L, Mamputu JC, Wiernsperger N, et al. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression inducedby leptin:inhibitory effect of metformin [J]. Diabetes, 2005, 54(7):2227-2234.
[12] 胡榕,洪华山,许昌声,等. 核因子-κB 在凝血酶促自发性高血压大鼠血管平滑肌细胞增殖中的作用[J].中国临床药理学与治疗学,2008,13 (6) :627 - 633.
[13] Hardie DG , Hawley SA,　Scott JW. AMP-activated protein kinase-development of the energy sensor concept [J]. J Physiol, 2006, 574(Pt 1):7-15.

[1]	王洁, 李龙, 陈凤, 刘胜菲. 二甲双胍干预肺纤维化发病机制的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 235-240.
[2]	王歆, 刘维英, 武晨, 开锦军, 梁雪杰, 常瑛璇. 二甲双胍调节AMPK/SREBP-1通路及在临床中的应用进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1049-1054.
[3]	丁嘉敏, 王友娣, 赵夏丽, 姜根风, 陈思文, 洪程程, 李书勤, 胡卫华. 生长激素和维生素E联合应用治疗薄型子宫内膜的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 857-862.
[4]	王珍, 全海燕, 洪陈亮, 袁李佳龙, 秦旭平. 游泳运动通过促进自噬改善糖尿病小鼠肾功能的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 632-638.
[5]	王新丽, 许霞青, 方寒冰, 郭玉忠. 佛波酯增强顺铂的抗肿瘤活性及降低其肾毒性的作用研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 535-543.
[6]	李岩岩, 方骁杰, 尹鑫, 孙曦, 饶春晖. circZNF124通过靶向miR-4262调控结直肠癌SW620细胞增殖、迁移及侵袭的机制研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1231-1239.
[7]	郝伟, 左东泽, 张俊秀, 蒋莉莉, 熊莺, 杨解人. 二甲双胍对TGF-β1诱导的大鼠肺泡上皮II型细胞间质转分化的影响[J]. 中国临床药理学与治疗学, 2021, 26(7): 744-752.
[8]	李筱旻, 金浩, 周文智, 杨汉跃, 邹婷, 郭洁, 徐平声. 盐酸二甲双胍缓释片在健康人体的生物等效性研究[J]. 中国临床药理学与治疗学, 2021, 26(4): 408-413.
[9]	彭福生, 黄小惠, 李鹏, 汤建儿. miR-34a通过调控雄激素受体基因抑制前列腺癌细胞系LNCaP增殖[J]. 中国临床药理学与治疗学, 2021, 26(1): 10-17.
[10]	侯彬, 黄维平, 尹中普, 胡守森. lncRNA PCAT19吸附miR-142-5p调控ING3基因表达抑制鼻咽癌细胞的增殖和侵袭[J]. 中国临床药理学与治疗学, 2020, 25(7): 721-727.
[11]	李桂女, 任少琳, 沈瑞明, 季永能, 蔡彩荣, 苏若. 二甲双胍联合糖皮质激素治疗伴糖耐量异常的系统性红斑狼疮患者的临床研究[J]. 中国临床药理学与治疗学, 2020, 25(6): 670-676.
[12]	程建平, 李珍, 赵晓琳, 杨梦媛, 冀希炜, 于久飞. 结肠癌患者血清中miR-186-5p表达的研究[J]. 中国临床药理学与治疗学, 2020, 25(10): 1097-1104.
[13]	聂娟，曹玉梅，杨冬梅，孙四玉，王巧琼，谢雪姣，庹勤慧. 夏枯草水提取物对血管平滑肌细胞增殖的影响及其机制研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 977-982.
[14]	郭良堂，林超，孙云，戴盛锋，张炳才，陈舒. 二甲双胍对多囊卵巢综合征患者疗效及其对患者脂肪组织miR-25水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 554-560.
[15]	丁秋花，史道华. 二甲双胍抗肿瘤作用的分子机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 350-354.